Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report

BACKGROUND: Metastatic or relapsed angiosarcoma has a poor prognosis and the efficacy of conventional chemotherapy is often limited. Apatinib, a novel tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor-2 (VEGFR2), has been approved for the treatment of advanced gas...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Lishu, Liu, Lizhu, Han, Bo, Han, Wei, Zhao, Meng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984462/
https://www.ncbi.nlm.nih.gov/pubmed/29855279
http://dx.doi.org/10.1186/s12885-018-4523-2
_version_ 1783328622883373056
author Yang, Lishu
Liu, Lizhu
Han, Bo
Han, Wei
Zhao, Meng
author_facet Yang, Lishu
Liu, Lizhu
Han, Bo
Han, Wei
Zhao, Meng
author_sort Yang, Lishu
collection PubMed
description BACKGROUND: Metastatic or relapsed angiosarcoma has a poor prognosis and the efficacy of conventional chemotherapy is often limited. Apatinib, a novel tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor-2 (VEGFR2), has been approved for the treatment of advanced gastric cancer. CASE PRESENTATION: Herein, we report a patient with advanced angiosarcoma, who received apatinib at a daily dose of 250 to 725 mg, resulting in a partial response for three months, which may be related to Kinase Insert Domain Receptor (KDR) gene amplification. CONCLUSION: Our experience reported here indicated that apatinib may be a useful therapeutic option for treatment of patients with advanced angiosarcoma.
format Online
Article
Text
id pubmed-5984462
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59844622018-06-07 Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report Yang, Lishu Liu, Lizhu Han, Bo Han, Wei Zhao, Meng BMC Cancer Case Report BACKGROUND: Metastatic or relapsed angiosarcoma has a poor prognosis and the efficacy of conventional chemotherapy is often limited. Apatinib, a novel tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor-2 (VEGFR2), has been approved for the treatment of advanced gastric cancer. CASE PRESENTATION: Herein, we report a patient with advanced angiosarcoma, who received apatinib at a daily dose of 250 to 725 mg, resulting in a partial response for three months, which may be related to Kinase Insert Domain Receptor (KDR) gene amplification. CONCLUSION: Our experience reported here indicated that apatinib may be a useful therapeutic option for treatment of patients with advanced angiosarcoma. BioMed Central 2018-05-31 /pmc/articles/PMC5984462/ /pubmed/29855279 http://dx.doi.org/10.1186/s12885-018-4523-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Yang, Lishu
Liu, Lizhu
Han, Bo
Han, Wei
Zhao, Meng
Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
title Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
title_full Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
title_fullStr Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
title_full_unstemmed Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
title_short Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
title_sort apatinib treatment for kit- and kdr-amplified angiosarcoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984462/
https://www.ncbi.nlm.nih.gov/pubmed/29855279
http://dx.doi.org/10.1186/s12885-018-4523-2
work_keys_str_mv AT yanglishu apatinibtreatmentforkitandkdramplifiedangiosarcomaacasereport
AT liulizhu apatinibtreatmentforkitandkdramplifiedangiosarcomaacasereport
AT hanbo apatinibtreatmentforkitandkdramplifiedangiosarcomaacasereport
AT hanwei apatinibtreatmentforkitandkdramplifiedangiosarcomaacasereport
AT zhaomeng apatinibtreatmentforkitandkdramplifiedangiosarcomaacasereport

Ejemplares similares